THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST
There is no benefit in helping create a miraculous new therapy that can cure people and save lives if no one except the super-rich can afford it. That’s why the California Institute for Regenerative Medicine (CIRM) has made creating a roadmap to help make new treatments both available and affordable for all Californians a central pillar of its new 5-year Strategic Plan.
New treatments based on novel new technologies often seem to come with a gob-smacking price tag. When Kymriah, a CAR-T cell cancer therapy, was approved it cost $475,000 for one treatment course. When the FDA approved Zolgensma to treat spinal muscular atrophy, a genetic disorder that causes muscle wasting and weakness, the cost was $2.1 million for one dose.
Part of the pricing is due to high manufacturing cost and the specialized resources needed to deliver the treatments. The treatments themselves are showing that they can be one-and-done options for patients, meaning just one treatment may be all they need to be cured. But even with all that innovation and promise the high price may impact access to patients in need.
At CIRM we believe that if California taxpayer money has helped researchers develop a new therapy, Californians should be able to get that therapy. To try and ensure they can we have created the Accessibility and Affordability Working Group (AAWG). The groups mission is to find a way to overcome the hurdles that stand between a patient and the treatment they need.
The AAWG will work with politicians and policy makers, researchers and regulators, insurance companies and patient advocate organizations to gather the data and information needed to make these therapies available and affordable. Dr. Le Ondra Clark Harvey, a CIRM Board member and mental health advocate, says the barriers we have to confront are not just financial, they are racial and ethnic too.
We have already created a unique model for delivering stem cell therapies to patients through our Alpha Stem Cell Clinic Network. We are now setting out to build on that with our commitment to creating Community Care Centers of Excellence. But having world-class clinics capable of delivering life-saving therapies is not enough. We also need to make sure that Californians who need these treatments can get them regardless of who they are or their ability to pay.
To learn more read out new Strategic Plan.
One thought on “Making stem cell and gene therapies available and affordable for all California patients”
A staggering amount of work and success, and a shining future ahead. Every page offers new directions: breakthroughs, development and challenges. As a patient advocate, I can only say, this is how we dreamed it would be. As Bob Klein would put it: Three cheers for CIRM! Don C. Reed http://www.stemcellbattles.net (sign up for my free newsletter!) Don Reed is author of the new book, “CALIFORNIA CURES! How the California Stem Cell Program is Fighting Your Incurable Disease!” available now at http://bit.ly/californiacures. For a 20% discount, use code “WSPY2PP20”! Reed is also Vice President of Public Policy for Americans for Cures Foundation; opinions voiced here as an individual may or may not reflect those of the Foundation. VISIT http://www.AmericansforCures.org